Cargando…
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
SIMPLE SUMMARY: Myeloma, a blood cancer, is rare and hard to diagnose. People often suffer irreversible organ damage by the time of diagnosis. Myeloma is preceded by a premalignant phase that is easily identifiable on a blood test. Currently, there is no screening for this, because most people do no...
Autores principales: | Bowcock, Stella, Atkin, Catherine, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Neal, Richard D., Planche, Tim, Karunanithi, Kamaraj, Jenkins, Stephen, Stern, Simon, Arnott, Sarah, Toth, Peter, Wandroo, Farooq, Dunn, Janet, Drayson, Mark T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341254/ https://www.ncbi.nlm.nih.gov/pubmed/37444449 http://dx.doi.org/10.3390/cancers15133337 |
Ejemplares similares
-
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
por: Drayson, Mark T, et al.
Publicado: (2019) -
TEAMM Work Saves Lives in Myeloma
por: Hallam, Simon
Publicado: (2018) -
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
por: Chicca, Ilaria J., et al.
Publicado: (2020) -
A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State
por: Elgabry, Gehad, et al.
Publicado: (2023) -
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)